A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Inclusion Criteria:

Phase 1: Patients with evaluable or measurable (by MRI or CT)
Hodgkin's Disease or Non-Hodgkin's Lymphoma. Phase 2: Patients with Measurable
Non-Hodgkin's Lymphomas (Indolent or Aggressive) only. - Patients with Indolent NHL must
be relapsed or refractory to at least one prior line of therapy (CHOP, CVP, chlorambucil
or fludaribine). Prior treatment with Rituximab is required. - Patients with Aggressive
NHL refractory to (or relapsed from) at least one CHOP-based therapy who have had prior
treatment with Rituximab and who are not candidates for high-dose chemotherapy or
autologous stem cell transplantation. - ECOG performance status 0-2 - Autologous stem
cell transplant recipients are eligible if 100 days have elapsed since procedure.
Exclusion Criteria: Phase 1: History of prior radioimmunotherapy (Bexxar, Zevalin); These
patients ARE permitted in the Phase 2 trial. - Current active malignancy besides NHL,
except excised non-melanoma skin cancer, in-situ cervical or bladder cancer or early stage
prostate cancer. - Patients with leptomeningeal of CNS lymphoma - Known allergy to
and/or receipt of treatments contraindicated by administration of G-CSF - Patients with
active Hepatitis B or C, or patients with HIV infection. - Pregnant or breast-feeding
females. - Previous treatment with a KSP inhibitor